Spruce Biosciences (OTC:SPRBD) Shares Up 40.9% – Time to Buy?

Spruce Biosciences, Inc. (OTC:SPRBD)’s share price traded up 40.9% on Thursday . The company traded as high as $12.75 and last traded at $12.40. 75,838 shares traded hands during mid-day trading, an increase of 675% from the average session volume of 9,786 shares. The stock had previously closed at $8.80.

Spruce Biosciences Stock Performance

The firm’s 50-day moving average price is $12.40 and its 200-day moving average price is $11.80. The stock has a market capitalization of $6.97 million, a PE ratio of -0.14 and a beta of 2.43.

Spruce Biosciences, Inc is a clinical-stage specialty biopharmaceutical company focused on developing targeted therapies for rare endocrine diseases. The company’s research strategy centers on modulating the hormonal axis to address underlying disease mechanisms rather than treating symptoms alone. By concentrating on orphan indications with high unmet medical need, Spruce aims to deliver novel treatment options for patients who have limited alternatives under current standard-of-care regimens.

Spruce’s lead product candidate is tildacerfont, an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist in development for adults with classic congenital adrenal hyperplasia (CAH).